Ankit Mahadevia is CEO & President at Spero Therapeutics, Inc. (SPRO). They have made 12 open-market trades across 1 company since 2018, most recently 2025-08-28.
CIK 0001720974
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRO | 703,294 | $774K |
Shares reported on the most recent Form 4, priced at the 2025-09-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | SELL | 2025-08-28 | 2025-09-03 | $1.97 | $13K | -9.6% | -1.4% | +5.8% |
| SPRO | SELL | 2025-02-05 | 2025-02-05 | $0.78 | $54K | -8.2% | -12.9% | -34.0% |
| SPRO | SELL | 2024-08-27 | 2024-08-29 | $1.35 | $8K | -2.9% | -2.9% | -18.1% |
| SPRO | SELL | 2024-02-02 | 2024-02-05 | $1.37 | $175K | +4.8% | +18.6% | +14.5% |
| SPRO | SELL | 2023-08-28 | 2023-08-30 | $1.26 | $11K | -10.3% | -16.6% | -20.0% |
| SPRO | SELL | 2023-02-03 | 2023-02-06 | $1.81 | $22K | -8.5% | -15.4% | +1.1% |
| SPRO | SELL | 2021-12-27 | 2021-12-29 | $14.58 | $117K | -12.4% | -26.6% | -45.6% |
| SPRO | SELL | 2020-11-03 | 2020-11-05 | $14.41 | $243K | +6.0% | +26.8% | +36.4% |
| SPRO | SELL · 10b5-1 | 2020-10-23 | 2020-10-27 | $14.25 | $285 | +3.6% | +26.6% | +43.5% |
| SPRO | SELL | 2020-10-13 | 2020-10-15 | $14.28 | $412K | +4.2% | +14.2% | +24.0% |
| SPRO | SELL · 10b5-1 | 2020-09-08 | 2020-09-10 | $14.25 | $11K | -2.1% | +39.5% | +74.5% |
| SPRO | SELL · 10b5-1 | 2020-07-07 | 2020-07-09 | $14.30 | $44K | -2.4% | -2.3% | -4.4% |
| SPRO | SELL | 2020-06-22 | 2020-06-29 | $14.31 | $416K | -1.3% | -8.9% | -29.5% |
| SPRO | SELL | 2018-07-05 | 2018-07-06 | $17.62 | $54K | -34.1% | -32.8% | -36.2% |
| SPRO | SELL | 2018-07-05 | 2018-07-06 | $17.63 | $140K | -34.1% | -32.8% | -36.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.